Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment

Loading...
Thumbnail Image
Penn collection
School of Dental Medicine::Departmental Papers (Dental)
Degree type
Discipline
Dentistry
Subject
angiotensin-converting-enzyme, biomarker, coronavirus disease, COVID-19, plasma marker, saliva marker, SARS-CoV-2 diagnosis/treatment, soluble Angiotensin-Converting Enzyme 2, biomarker in plasma/saliva, Corona virus, COVID-19 disease, ACE2 activity/concentration, RAS pathway
Funder
Grant number
Copyright date
2022
Distributor
Related resources
Author
Henry Daniell; Smruti K. Nair; Yao Shi; Ping Wang; Kathleen T. Montone; Pamela A. Shaw; Grace H. Choi; Danyal Ghani; JoEllen Weaver; Daniel J. Rader; Kenneth B. Margulies; Ronald G. Collman; Krzysztof Laudanski; Katharine J. Bar
Contributor
Abstract

Although several therapeutics are used to treat coronavirus disease 2019 (COVID-19) patients, there is still no definitive metabolic marker to evaluate disease severity and recovery or a quantitative test to end quarantine. Because severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infects human cells via the angiotensin-converting-enzyme 2 (ACE2) receptor and COVID-19 is associated with renin-angiotensin system dysregulation, we evaluated soluble ACE2 (sACE2) activity in the plasma/saliva of 80 hospitalized COVID-19 patients and 27 non-COVID-19 volunteers, and levels of ACE2/Ang (1–7) in plasma or membrane (mACE2) in lung autopsy samples. sACE2 activity was markedly reduced (p < 0.0001) in COVID-19 plasma (n = 59) compared with controls (n = 27). Nadir sACE2 activity in early hospitalization was restored during disease recovery, irrespective of patient age, demographic variations, or comorbidity; in convalescent plasma-administered patients (n = 45), restoration was statistically higher than matched controls (n = 22, p = 0.0021). ACE2 activity was also substantially reduced in the saliva of COVID-19 patients compared with controls (p = 0.0065). There is a strong inverse correlation between sACE2 concentration and sACE2 activity and Ang (1–7) levels in participant plasmas. However, there were no difference in membrane ACE2 levels in lungs of autopsy tissues of COVID-19 (n = 800) versus other conditions (n = 300). These clinical observations suggest sACE2 activity as a potential biomarker and therapeutic target for COVID-19.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2022-09-08
Journal title
Molecular Therapy
Volume number
Issue number
Publisher
The Authors
Journal Issue
Comments
Recommended citation
Collection